SCHEMBL2965098

SCHEMBL2965098

CN(C)CCCn1nc(-c2ccc3[nH]c(Cc4ccccc4)nc3c2)c2c(N)ncnc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 4/20 0.51
▸ PRKDC P78527 4/20 0.51
▸ PIK3CA P42336 3/20 0.51
▸ PIK3CB P42338 3/20 0.51
▸ PIK3CG P48736 3/20 0.51
▸ IGF1R P08069 4/20 0.49
▸ EGFR P00533 1/20 0.49
▸ ERBB2 P04626 1/20 0.49
▸ FYN P06241 3/20 0.47
▸ YES1 P07947 2/20 0.47
▸ FGR P09769 2/20 0.47
▸ SRC P12931 2/20 0.47
▸ LYN P07948 1/20 0.47
▸ HDAC1 Q13547 6/20 0.46
▸ MTOR P42345 5/20 0.46
▸ KDR P35968 3/20 0.46
▸ HDAC3 O15379 2/20 0.46
▸ HDAC2 Q92769 2/20 0.46
▸ HDAC8 Q9BY41 2/20 0.46
▸ HDAC6 Q9UBN7 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2966913 0.89 RET (0.60) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL2959065 0.81 SRC (0.60) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL2967660 0.78 IGF1R (0.55) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL2960985 0.78 IGF1R (0.68) IGF1REGFRERBB2SRC
SCHEMBL2965908 0.76 IGF1R (0.71) IGF1REGFRERBB2
SCHEMBL2967567 0.76 IGF1R (0.54) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL2967840 0.76 IGF1R (0.58) IGF1REGFRERBB2FYN
SCHEMBL2958098 0.75 IGF1R (0.69) IGF1REGFRERBB2
SCHEMBL2967474 0.75 IGF1R (0.76) IGF1REGFRERBB2
SCHEMBL2958786 0.73 IGF1R (0.68) IGF1REGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP claimed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US claimed
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP disclosed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US disclosed
EP-1973917-A2 PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2008-10-01 — — EP disclosed
US-20070203143-A1 PROTEIN KINASE INHIBITORS ABBVIE INC. 2007-08-30 — — US disclosed
WO-2007079164-A2 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203143-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 PIK3CD 264/4885PRKDC 11/4885PIK3CA 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback